If you are considering a bmac injection, one of the first practical questions is whether insurance will help pay for it. That matters because BMAC is a specialist regenerative treatment, and the answer can affect not only your budget, but also how realistic the treatment feels as an option.

The short answer is usually no

In most cases, insurance does not cover a bmac injection. Regenesis says on its fees page that most insurance providers do not cover regenerative treatments, and recommends checking directly with your insurer before booking. That is the clearest starting point for patients looking at BMAC through a private clinic route.

This broader pattern is not unique to one clinic. Hospital for Special Surgery says insurance companies do not yet cover regenerative medicine therapies, and OhioHealth’s regenerative therapy FAQ states plainly that BMAC is not covered by insurance companies at this time. In other words, a bmac injection is usually treated as an out-of-pocket treatment rather than a routine insured procedure.

Why insurers often do not cover it

The main reason is that regenerative orthopaedic treatments are still often viewed as investigational, elective, or not yet sufficiently established for routine reimbursement. A recent 2025 review noted that insurance payers generally do not cover mesenchymal stem-cell-based therapies for orthopaedic applications, which reflects the same wider reimbursement pattern seen with BMAC and other regenerative treatments.

That does not mean a bmac injection has no evidence behind it. Regenesis explains that BMAC is being studied for osteoarthritis, cartilage damage, tendon injury, ligament injury, and chronic joint pain, but it also notes that research findings are mixed and that larger, longer-term studies are still needed. Insurers often move more slowly than clinics or patients would like when evidence is still developing.

So, if you are asking why a bmac injection is not commonly covered, it is usually less about one insurer being awkward and more about how regenerative medicine is currently classified. From an insurer’s perspective, treatments that are still building their long-term evidence base often sit outside standard reimbursement pathways.

Are there any exceptions?

There can be exceptions, but they are not something most patients should assume. Some providers note that rare cases involving special plans, workers’ compensation arrangements, or treatment combined with another procedure may create different funding situations. HSS, for example, notes that when regenerative treatments are performed alongside an operation or another insured treatment, the other parts of the care pathway may be covered even if the regenerative component is not.

That is why it is worth checking your policy directly rather than relying on a forum post or a general assumption. A bmac injection may still be excluded in most routine cases, but insurers and plans are not all worded in exactly the same way. It is always worth asking for a written answer so you know where you stand before committing financially.

What to ask your insurer before you book

If you are considering a bmac injection, ask your insurer whether regenerative orthopaedic procedures are covered at all, whether bone marrow aspirate concentrate is listed specifically, and whether cover changes if the treatment is performed alongside imaging, consultation, or another procedure. It is also worth asking whether there are any pre-authorisation requirements or exclusions for treatments considered experimental or elective.

This can save a lot of confusion later. Some patients assume that because a treatment uses their own cells, or because it is done by a specialist, it will automatically be treated like other orthopaedic care. A bmac injection does not usually fall into that routine category, which is exactly why it is worth checking the wording of your policy rather than guessing. 

What this means in practical terms

For most people, the practical answer is that a bmac injection should be budgeted for as a self-pay treatment unless your insurer explicitly confirms otherwise. Regenesis’ current model reflects that reality by listing consultation fees publicly and explaining that regenerative treatment quotes are personalised after review, while also noting that most insurers do not cover these treatments. 

That does not mean the treatment is off the table. It simply means the financial planning side needs to be part of the decision from the start. If you are seriously considering a bmac injection, the best next step is to combine two things: a proper clinical assessment to find out whether it is appropriate, and a direct conversation with your insurer so you know whether the treatment is likely to be self-funded. Read more from Regenesis or book a consultation to discuss whether BMAC may be suitable for your condition and what the likely costs may involve.